Recently, GlaxoSmithKline (GSK) announced that the US Food and Drug Administration (FDA) has extended the review period for Glaxo’s oncology candidate, trametinib, by three months. A...(read more
GlaxoSmithKline(GSK) recently announced the receipt of marketing authorization for its four-strain seasonal influenza vaccine in Germany and the UK. The vaccine will be marketed as...(read more
In 2008, GlaxoSmithKline (NYSE: GSK) acquired its subsidiary for $720 million. Now it plans to absorb the company into its research and development portfolio...